NLS Pharmaceutics Merges with Kadimastem to Form NewCelX

NewcelX (f/k/a NLS Pharmaceutics) Completes Merger with Kadimastem Ltd.

October 30, 2025

Biotechnology

NewcelX Ltd. (f/k/a NLS Pharmaceutics) completed a merger with Kadimastem Ltd., effective October 30, 2025, forming a combined biotechnology company that will trade on the Nasdaq Capital Market under the ticker "NCEL" starting October 31, 2025. Under the merger, Kadimastem shareholders received 0.706 NewcelX shares per Kadimastem share; the combined company will advance cell‑therapy and small‑molecule programs (including AstroRx and IsletRx) with headquarters in Zurich and R&D operations in Ness Ziona, Israel.

Norstella and Citeline Merge to Create $5B Global Pharma Technology Company

June 28, 2022

Data & Analytics

Norstella (the group of Evaluate, MMIT, Panalgo and The Dedham Group) announced an agreement to merge with Citeline (formerly Pharma Intelligence) to form a combined global pharmaceutical technology and intelligence business valued at about $5 billion. The combination brings clinical trial intelligence, commercial data and real‑world analytics together to offer an end‑to‑end suite of solutions for life sciences companies; the deal involves financial sponsors including Hg (Norstella) and Warburg Pincus (Citeline).

Nordic Capital and Astorg Acquire Cytel from New Mountain Capital

December 21, 2020

Healthcare Services

Nordic Capital and Astorg have agreed to jointly acquire Cytel Inc. from New Mountain Capital. Cytel, a Waltham, Massachusetts–based provider of clinical trial design software, biometrics services and advanced analytics with more than 1,500 employees, will continue to be led by CEO Josh Schultz while the new owners invest to accelerate product development and growth; terms were not disclosed.

Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

December 13, 2022

Medical Devices

Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.

Azelis Acquires Solchem Nature S.L. to Strengthen Nutraceutical Offering in Spain

April 7, 2025

Food & Beverage

Azelis has acquired 100% of Solchem Nature S.L., a Barcelona-based distributor of raw materials and premium ingredients for the nutraceutical and dietary supplements market. The deal expands Azelis's presence in Spain and adds Solchem's ~14-person team and network of over 250 customers to Azelis's EMEA nutraceutical platform.

Catabasis Pharmaceuticals Acquires Quellis Biosciences Inc.

January 29, 2021

Biotechnology

Catabasis Pharmaceuticals has acquired Quellis Biosciences in a stock-for-stock merger to obtain Quellis' lead preclinical monoclonal antibody program QLS-215 for hereditary angioedema. Concurrent with the acquisition, Catabasis completed a private placement (PIPE) led by Perceptive Advisors and other institutional investors to raise approximately $110 million to fund IND-enabling studies and early clinical trials of QLS-215.